国产吉西他滨联合顺铂治疗晚期肺鳞癌及肺腺癌疗效分析

目的观察国产吉西他滨（泽菲）联合顺铂对晚期肺鳞癌与肺腺癌治疗疗效差别,为临床上晚期肺癌的化疗药物筛选提供依据。方法肺鳞癌组36例与肺腺癌组34例分别接受吉西他滨（1000 mg/m2）加顺铂（75 mg/m2）化疗,每21 d为1周期,每2个周期评价疗效。结果鳞癌36例和腺癌组34例均能进行临床评价。鳞癌组中部分缓解（PR）14例（38.9%）,稳定（SD）16例（44.4%）,进展（PD）6例（16.7%）,有效率（RR）为38.9%,疾病控制率（DCR）为83.3%,中位肿瘤进展时间（TTP）为5.7个月,中位生存期为12个月,1年生存率为47.2%（17/36））。腺癌组中PR 11例（32.4%）,SD 18例（52.9%）,PD 5例（14.7%）,RR 32.4%,DCR 85.3%,中位TTP为5.3个月,中位生存期为9个月,1年生存率为32.4%（11/34）。结论吉西他滨对肺鳞癌与肺腺癌的疾病控制率相近,但对鳞癌表现出比腺癌更高的生存时间与生存率。

Efficacy of domestic gemcitabine combined with cisplatin in treatment of advanced squamous carcinoma and adenocarcinoma of lung

Objective To evaluate the difference in efficacy of domestic gemcitabine combined with cisplatin in treatment of advanced squamous carcinoma and adenocarcinoma of lung.Methods Thirty-six patients with squamous carcinoma and 34 patients with adenocarcinoma of lung received chemotherapy with gemcitabine（1 000mg/m2） plus cisplatin（75mg/m2）,every 21 days as a cycle.The therapeutic efficacy was evaluated after 2 cycles of chemotherapy.Results Thirty-six patients with squamous carcinoma and 34 patients with adenocarcinoma of lung could be evaluated objectively.In squamous carcinoma patients,partial response（PR） was 14（38.9%）,stable disease（SD） was 16（44.4%）,progressive disease（PD） was 6（16.7%）,response rate（RR） was 38.9%,disease control rate（DCR） was 83.3%.The median time to progression（TTP） was 5.7 months.Median survival time was 12 months and one-year survival rate was 47.2%（17/36）.In adenocarcinoma patients,PR was 11（32.4%）,SD was 18（52.9%）,PD was 5（14.7%）,RR was 32.4%,DCR was 85.3%.The median TTP was 5.3 months.Median survival time was 9 months and one-year survival rate was 32.4%（11/34）.Conclusion The control of squamous carcinoma and adenocarcinoma of lung treated by gemcitabine was similar,but the survival time and survival rate of patients with squamous carcinoma are higher than those of patients with adenocarcinoma.